Consecutive or selectively included high bleeding risk patients
in the MASTER DAPT screening log and trial

J 2024

Consecutive or selectively included high bleeding risk patients in the MASTER DAPT screening log and trial

LANDI, Antonio, Dik HEG, Enrico FRIGOLI, Pim A L TONINO, Pascal VRANCKX et. al.

Základní údaje

Originální název

Consecutive or selectively included high bleeding risk patients in the MASTER DAPT screening log and trial

Autoři

LANDI, Antonio, Dik HEG, Enrico FRIGOLI, Pim A L TONINO, Pascal VRANCKX, Suzanne POURBAIX, Bernard CHEVALIER, Andres INIGUEZ, Eduardo PINAR, Maciej LESIAK, Petr KALA (203 Česká republika, domácí), Michael DONAHUE, Stephan WINDECKER, Marco ROFFI, Pieter C SMITS a Marco VALGIMIGLI

Vydání

European Journal of Internal Medicine, AMSTERDAM, ELSEVIER, 2024, 0953-6205

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 8.000 v roce 2022

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.ejim.2024.04.016

UT WoS

001287622700001

Klíčová slova anglicky

High bleeding risk; Antiplatelet therapy; Dual antiplatelet therapy; Percutaneous coronary intervention

Štítky

14110211, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 19. 8. 2024 08:33, Mgr. Tereza Miškechová

Anotace

V originále

Aims: Screening logs have the potential to appraise the actual prevalence and distribution of predefined patient subsets, avoiding selection biases, which are inevitably and potentially present in randomised trials and real- world registries, respectively. We aimed to assess the prevalence of high bleeding risk (HBR) characteristics in the real world and the external validity of the MASTER DAPT trial. Methods and results: All consecutive patients who underwent percutaneous coronary intervention (PCI) for at least two consecutive weeks across 65 sites participating in the trial were entered into a screening log. Of 2,847 consecutive patients, 1,098 (38.6 %) were HBR and 109 (9.9 %) consented for trial participation. PRECISE-DAPT score > 25 was the most frequent HBR feature, followed by advanced age, use of oral anticoagulation (OAC) and anaemia. Compared with consecutive HBR patients, consenting patients were older (> > 75 years: 69 % versus 62 %, absolute standardized difference [SD] 0.16), more frequently male (78 % versus 71 %, absolute SD 0.18), had higher use of OAC (38 % versus 20 %, absolute SD 0.39), treatment with steroids or nonsteroidal antiinflammatory drugs (10 % versus 5 %, SD 0.16), and prior cerebrovascular events (10 % versus 6 %, , absolute SD 0.18) but lower PRECISE DAPT score > 25 (54 % versus 66 %, absolute SD 0.24). Conclusions: The HBR criteria distribution differed between consecutive versus selectively included HBR patients, suggesting the existence of selection biases in the trial population.

Citovat

LANDI, Antonio, Dik HEG, Enrico FRIGOLI, Pim A L TONINO, Pascal VRANCKX, Suzanne POURBAIX, Bernard CHEVALIER, Andres INIGUEZ, Eduardo PINAR, Maciej LESIAK, Petr KALA, Michael DONAHUE, Stephan WINDECKER, Marco ROFFI, Pieter C SMITS a Marco VALGIMIGLI. Consecutive or selectively included high bleeding risk patients in the MASTER DAPT screening log and trial. European Journal of Internal Medicine. AMSTERDAM: ELSEVIER, 2024, roč. 126, August 2024, s. 89-94. ISSN 0953-6205. Dostupné z: https://dx.doi.org/10.1016/j.ejim.2024.04.016.

@article{2423720,
   author = {Landi, Antonio and Heg, Dik and Frigoli, Enrico and Tonino, Pim A L and Vranckx, Pascal and Pourbaix, Suzanne and Chevalier, Bernard and Iniguez, Andres and Pinar, Eduardo and Lesiak, Maciej and Kala, Petr and Donahue, Michael and Windecker, Stephan and Roffi, Marco and Smits, Pieter C and Valgimigli, Marco},
   article_location = {AMSTERDAM},
   article_number = {August 2024},
   doi = {http://dx.doi.org/10.1016/j.ejim.2024.04.016},
   keywords = {High bleeding risk; Antiplatelet therapy; Dual antiplatelet therapy; Percutaneous coronary intervention},
   language = {eng},
   issn = {0953-6205},
   journal = {European Journal of Internal Medicine},
   title = {Consecutive or selectively included high bleeding risk patients in the MASTER DAPT screening log and trial},
   url = {https://www.sciencedirect.com/science/article/pii/S0953620524001766?via%3Dihub},
   volume = {126},
   year = {2024}
}

TY  - JOUR
ID  - 2423720
AU  - Landi, Antonio - Heg, Dik - Frigoli, Enrico - Tonino, Pim A L - Vranckx, Pascal - Pourbaix, Suzanne - Chevalier, Bernard - Iniguez, Andres - Pinar, Eduardo - Lesiak, Maciej - Kala, Petr - Donahue, Michael - Windecker, Stephan - Roffi, Marco - Smits, Pieter C - Valgimigli, Marco
PY  - 2024
TI  - Consecutive or selectively included high bleeding risk patients in the MASTER DAPT screening log and trial
JF  - European Journal of Internal Medicine
VL  - 126
IS  - August 2024
SP  - 89-94
EP  - 89-94
PB  - ELSEVIER
SN  - 09536205
KW  - High bleeding risk
KW  - Antiplatelet therapy
KW  - Dual antiplatelet therapy
KW  - Percutaneous coronary intervention
UR  - https://www.sciencedirect.com/science/article/pii/S0953620524001766?via%3Dihub
N2  - Aims: Screening logs have the potential to appraise the actual prevalence and distribution of predefined patient subsets, avoiding selection biases, which are inevitably and potentially present in randomised trials and real- world registries, respectively. We aimed to assess the prevalence of high bleeding risk (HBR) characteristics in the real world and the external validity of the MASTER DAPT trial. Methods and results: All consecutive patients who underwent percutaneous coronary intervention (PCI) for at least two consecutive weeks across 65 sites participating in the trial were entered into a screening log. Of 2,847 consecutive patients, 1,098 (38.6 %) were HBR and 109 (9.9 %) consented for trial participation. PRECISE-DAPT score > 25 was the most frequent HBR feature, followed by advanced age, use of oral anticoagulation (OAC) and anaemia. Compared with consecutive HBR patients, consenting patients were older (> > 75 years: 69 % versus 62 %, absolute standardized difference [SD] 0.16), more frequently male (78 % versus 71 %, absolute SD 0.18), had higher use of OAC (38 % versus 20 %, absolute SD 0.39), treatment with steroids or nonsteroidal antiinflammatory drugs (10 % versus 5 %, SD 0.16), and prior cerebrovascular events (10 % versus 6 %, , absolute SD 0.18) but lower PRECISE DAPT score > 25 (54 % versus 66 %, absolute SD 0.24). Conclusions: The HBR criteria distribution differed between consecutive versus selectively included HBR patients, suggesting the existence of selection biases in the trial population.
ER  -

LANDI, Antonio, Dik HEG, Enrico FRIGOLI, Pim A L TONINO, Pascal VRANCKX, Suzanne POURBAIX, Bernard CHEVALIER, Andres INIGUEZ, Eduardo PINAR, Maciej LESIAK, Petr KALA, Michael DONAHUE, Stephan WINDECKER, Marco ROFFI, Pieter C SMITS a Marco VALGIMIGLI. Consecutive or selectively included high bleeding risk patients in the MASTER DAPT screening log and trial. \textit{European Journal of Internal Medicine}. AMSTERDAM: ELSEVIER, 2024, roč.~126, August 2024, s.~89-94. ISSN~0953-6205. Dostupné z: https://dx.doi.org/10.1016/j.ejim.2024.04.016.

Podrobný výpis o publikaci